EL earnings analysis
What we found in EL's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Estée Lauder’s fiscal 2026 results show a meaningful operational recovery: revenue rose 5%, gross margin expanded to 75.5%, operating income returned to $780 million, and operating cash flow improved to $1.773 billion. Growth was led by fragrance, Mainland China and EUKEM, while the company’s Beauty Reimagined and PRGP initiatives improved margins but remain associated with $1.748 billion of expected restructuring charges and approximately 10,000 position reductions. The outlook is balanced by tariff uncertainty, travel-retail volatility, elevated debt, and sensitivity in several major brand valuations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue and gross margin recovered
- Fiscal 2026 net sales increased 5% to $15.049 billion, following an 8% decline to $14.326 billion in fiscal 2025 from $15.608 billion in fiscal 2024. Gross margin improved to 75.5% from 74.0% in fiscal 2025 and 71.7% in fiscal 2024.
- Operating profitability rebounded
- Operating income increased to $780 million, or a 5.2% margin, from a $785 million loss and a negative 5.5% margin in fiscal 2025. On an adjusted basis excluding specified charges, operating income increased 47% to $1.687 billion from $1.146 billion.
- Earnings returned to positive
- Net earnings attributable to Estée Lauder increased to $182 million and diluted EPS to $0.50, versus a $1.133 billion net loss and $(3.15) diluted EPS in fiscal 2025; adjusted diluted EPS increased 66% to $2.51 from $1.51.
- Fragrance led category growth
- Fragrance was the strongest product category, with revenue up 12% to $2.779 billion and operating income improving to $204 million from a $378 million loss. Le Labo, TOM FORD and KILIAN PARIS together contributed approximately $221 million of fragrance revenue growth.
- China and Asia drove recovery
- Mainland China revenue increased 12% to $3.058 billion, while EUKEM revenue increased 6% to $3.794 billion. Mainland China operating income rose 92% to $373 million, and Asia/Pacific operating income increased to $823 million from $180 million.
- Cash generation and capex improved
- Operating cash flow increased to $1.773 billion from $1.272 billion in fiscal 2025 and $2.360 billion in fiscal 2024. Capital expenditures declined to $457 million from $602 million in fiscal 2025 and $919 million in fiscal 2024, while cash and equivalents rose to $3.498 billion.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Restructuring costs and execution risk
- The Restructuring Program expanded to an estimated final net reduction of approximately 10,000 global positions, versus a previously announced range of 9,000 to 10,000. Total expected restructuring and other charges increased to $1.748 billion before tax, above the prior $1.500 billion to $1.700 billion range; accrued restructuring charges are expected to require approximately $530 million of cash payments in fiscal 2027.
- Tariffs threaten fiscal 2027 margins
- The company anticipates tariffs will adversely affect fiscal 2027 profitability and cash flows, and states that the impact could be material depending on actual rates and countries imposing tariffs. Tariffs already contributed to unfavorable manufacturing costs and other items in fiscal 2026, despite approximately $250 million of favorable foreign-currency translation benefiting reported sales.
- Fragile trademark valuations
- Brand impairment sensitivity remains material despite no impairment charge in fiscal 2026. Dr.Jart+ fair value exceeded its $37 million carrying value by only 4%, while an estimated 4% decline in future net sales or a 30-basis-point increase in WACC would have reduced fair value to approximately carrying value; TOM FORD had a $1.805 billion carrying value and only 19% excess fair value.
- Travel retail and geopolitical exposure
- Asia travel retail remains exposed to retailer changes and Chinese consumer behavior. The filing identifies transitory pressure from the change in duty-free retailers servicing the Beijing and Shanghai airports, while locations affected by the Middle East conflict represented approximately 2% of consolidated fiscal 2025 net sales.
- Debt and ratings pressure
- Leverage remains elevated: total debt was $7.306 billion at June 30, 2026, equal to 66% of total capitalization versus 65% in fiscal 2025. Standard & Poor’s and Moody’s both rated the company’s long-term debt with a negative outlook as of August 12, 2026.
- Talcum claims continue to rise
- Talcum litigation exposure increased to 118 pending U.S. state-court cases at June 30, 2026 from 84 cases a year earlier; 100 cases were filed and 66 resolved during fiscal 2026. The company states that adverse outcomes on pending or future claims could be material, although losses beyond recorded amounts cannot be reasonably estimated.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.5
- Gross margin
- 75.5%
- Operating margin
- 5.2%
- Segment
- Skin Care: $7.338 billion revenue; $1.416 billion operating income
- Segment
- Makeup: $4.276 billion revenue; $70 million operating loss
- Segment
- Fragrance: $2.779 billion revenue; $204 million operating income
- Segment
- Hair Care: $565 million revenue; $4 million operating loss
What they said about what is next.
The 10-K does not provide quantitative fiscal 2027 revenue or EPS guidance; annual outlook is generally provided in the fiscal fourth-quarter earnings press release or call. The filing does state that tariffs are anticipated to adversely affect fiscal 2027 profitability and cash flows, potentially materially, and that the Restructuring Program is expected to be substantially completed by the end of fiscal 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 1, 2026
- The Estée Lauder Companies reported Q3 FY2026 results, achieving revenue of $3.712 billion, a 5% increase year-over-year, but fell short of expectations for EPS, delivering $0.24 compared to an estimated $0.65. Key…
- 10-K · August 20, 2025
- The 10-K outlines a strategic pivot launched in February 2025 called “Beauty Reimagined” to accelerate consumer coverage, innovation, consumer-facing investments and efficiencies while reorganizing geographic reporting…
- 10-Q · October 31, 2024
- Estée Lauder reported quarterly revenue of $3,361 million, down $157 million (≈4.5%) versus the prior-year quarter, while gross margin improved to 72.4%. The company swung to a net loss of $156 million (diluted loss…
- 10-K · August 19, 2024
- Estée Lauder emphasizes a multi-brand, omnichannel luxury strategy supported by continued investment in R&D and manufacturing capacity. Key 2024 developments include R&D spend of $360 million, completion of a new Japan…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever